WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) today announced it was awarded a seven-year contract under the Clinical Research Support Services (CRSS) program of the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
The CRSS critical infrastructure contract provides support for assessing and auditing investigative sites and laboratories, capacity building, biostatistics, site training and data management. PPD will provide a broad range of clinical and other related research support services for the NIAID/DAIDS-supported clinical research portfolio and other infectious diseases relevant to HIV-infected and at-risk populations.
“We are pleased to help NIAID develop and maintain a strong clinical infrastructure to meet the needs of DAIDS’ scientific agenda,” said William Sharbaugh, chief operating officer of PPD. “Our dedicated professionals are committed to supporting the agencies’ initiatives to improve health.”
This agreement complements a long-standing collaboration between PPD and NIAID that, in March, was extended through 2024, covering support for a broad scope of research related to HIV or HIV co-infections.
About PPD
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 47 countries and approximately 20,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.
